NextCell Pharma Enters Strategic Partnership with Fujifilm Irvine Scientific

• NextCell Pharma AB has announced a strategic collaboration with Fujifilm Irvine Scientific Inc. to jointly offer mesenchymal stromal cell (MSC) products with compatible culture media and cryopreservation solutions.

• The partnership aims to support cell therapy researchers with a standardised and reliable MSC reference system.

NextCell Pharma AB has entered a strategic collaboration with Fujifilm Irvine Scientific Inc. to combine their respective strengths in mesenchymal stromal cells (MSCs) and cell culture media. The partnership aims to provide researchers and developers in the cell therapy field with a combined offering of standardised MSC products, optimised media, and cryopreservation solutions.

The collaboration builds on NextCell’s development of a research-use-only umbilical cord MSC product in 2024. This product was developed using the company’s proprietary in-house expertise and is targeted at the commercial market. Fujifilm brings over five decades of experience in developing cell culture solutions for life sciences and medical applications.

The joint solution is designed to support researchers by offering a high-quality, standardised MSC reference material, along with tailored media and cold storage products. This is intended to create a reliable platform for the development and validation of new therapies.

“We have worked closely together to develop this business relationship and are proud to be able to announce this new opportunity to our shareholders,” said Dr Lindsay Davies, CSO at NextCell.

Mathias Svahn, CEO at NextCell, added: “This is a new business venture for NextCell, and we are excited to collaborate with Fujifilm, combining our expertise to build a strong partnership for the future.”